Mutation of the MYL3 gene in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy
dc.contributor.author | Mavilakandy, Akash | |
dc.date.accessioned | 2022-03-24T11:25:39Z | |
dc.date.available | 2022-03-24T11:25:39Z | |
dc.date.issued | 2022-03 | |
dc.identifier.citation | Mavilakandy, A., & Ahamed, H. (2022). Mutation of the MYL3 gene in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy. BMJ case reports, 15(3), e244573. https://doi.org/10.1136/bcr-2021-244573 | en_US |
dc.identifier.other | 10.1136/bcr-2021-244573 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12904/15299 | |
dc.description.abstract | In this study, we discuss a female patient referred to cardiology with left ventricular hypertrophy at mid-ventricular segments resulting in a mid-cavitary obstruction and a left ventricular apical aneurysm. The patient had normal epicardial coronary arteries, but presented with recurrent cerebrovascular events. The patient had a positive family history for sudden cardiac death. Cardiac MRI detected positive features of left ventricular mid-cavity obstruction, left ventricular apical aneurysm and delayed gadolinium enhancement, with Holter monitoring assessment displaying segments of non-sustained ventricular tachycardia. Genetic analysis detected an myosin light chain 3 (MYL3) gene mutation. The patient will be referred to receive an implantable cardioverter defibrillator.The MYL3 gene mutation is a rare variant in patients with familial hypertrophic cardiomyopathy. To our knowledge, the presence of a left ventricular apical aneurysm has not been previously reported in literature concerning the MYL3 gene mutation. The presence of this abnormality further increases the risk of sudden cardiac death. | |
dc.description.uri | https://casereports.bmj.com/content/15/3/e244573 | en_US |
dc.subject | arrhythmias | en_US |
dc.subject | hypertrophic cardiomyopathy | en_US |
dc.subject | genetic screening | en_US |
dc.title | Mutation of the MYL3 gene in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy | en_US |
dc.type | Article | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |
rioxxterms.version | NA | en_US |
rioxxterms.versionofrecord | https://doi.org/10.1136/bcr-2021-244573 | en_US |
rioxxterms.type | Journal Article/Review | en_US |
refterms.panel | Unspecified | en_US |
html.description.abstract | In this study, we discuss a female patient referred to cardiology with left ventricular hypertrophy at mid-ventricular segments resulting in a mid-cavitary obstruction and a left ventricular apical aneurysm. The patient had normal epicardial coronary arteries, but presented with recurrent cerebrovascular events. The patient had a positive family history for sudden cardiac death. Cardiac MRI detected positive features of left ventricular mid-cavity obstruction, left ventricular apical aneurysm and delayed gadolinium enhancement, with Holter monitoring assessment displaying segments of non-sustained ventricular tachycardia. Genetic analysis detected an myosin light chain 3 (MYL3) gene mutation. The patient will be referred to receive an implantable cardioverter defibrillator.The MYL3 gene mutation is a rare variant in patients with familial hypertrophic cardiomyopathy. To our knowledge, the presence of a left ventricular apical aneurysm has not been previously reported in literature concerning the MYL3 gene mutation. The presence of this abnormality further increases the risk of sudden cardiac death. | en_US |
rioxxterms.funder.project | 94a427429a5bcfef7dd04c33360d80cd | en_US |